Generation Bio

Generation Bio EBITDA Margin

Delisted

The EBITDA Margin of Generation Bio (GBIO) as of Nov 10, 2026 is -715.82 %. In the previous year, EBITDA Margin was -2,346.93 % — a change of -69.50% (higher).

EBITDA Margin

-715.82 %

YoY

-69.50%

Last updated:

EBITDA Margin of Generation Bio is 2024 -715.82 % . EBITDA Margin of Generation Bio was 2023 -2,346.93 % . It decreases by -69.50% higher compared to the previous year.

The Generation Bio EBITDA Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Margin
Date
EBITDA Margin
Jan 1, 2018
-103,594.44 USD
Jan 1, 2022
-16,043.41 USD
Jan 1, 2023
-2,346.93 USD
Jan 1, 2024
-715.82 USD
The Generation Bio EBITDA Margin history
YEAREBITDA MarginYoY
-715.82 %-69.50%
-2,346.93 %-85.37%
-16,043.41 %-84.51%
-103,594.44 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Generation Bio Stock analysis

What does Generation Bio do? Generation Bio Co. is a genetic medicines company headquartered in Cambridge, Massachusetts, that focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. The firm is developing a class of gene therapy utilizing its non-viral gene therapy platform to deliver genetic payloads to a range of tissues. The company’s non-viral gene therapy platform includes its DNA construct called closed-ended DNA (ceDNA), its cell-targeted lipid nanoparticle delivery system (ctLNP) and its established, scalable capsid-free manufacturing process. The firm is engineering its gene therapies to be redosable, which enable patient titration to reach the desired therapeutic expression and to maintain efficiency in a patient’s life. The firm is a preclinical stage company and have not identified a product candidate. Generation Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Generation Bio stock

EBITDA Margin of Generation Bio is -715.82 % in 2024.

EBITDA Margin of Generation Bio changed from -2,346.93 % to -715.82 %, representing a -69.50% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA Margin Generation Bio since 2006 – with annual values, charts, and detailed analysis.

EBITDA Margin shows what percentage of revenue converts to EBITDA. It normalizes for depreciation and capital structure differences.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBITDA Margin's Generation Bio with sector peers and the industry average to assess whether it is attractive.

To evaluate EBITDA Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBITDA Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Generation Bio

All Key Metrics — Generation Bio